Inhibitor proteazomu - bortezomib (Velcade) - v léčbě refrakterního mnohočetného myelomu První zkušenosti v České republice

• Title in English: Bortezomib (Velcade) in relapsed/refractory multiple myeloma-the first experience in the Czech Republic
• Authors: ŠPIČKA Ivan; HÁJEK Roman; VYTŘASOVÁ M.; MAISNAR Vladimír; GREGORA E.; SCHUTZOVÁ M.; ŠTRAUB J.; ŠČUDLA Vlastimil; ADAM Zdeněk; KLENER P.
• Year of publication: 2005
• Type: Article in Periodical
• Magazine / Source: Časopis lékařů českých
• MU Faculty or unit: Faculty of Medicine
• Field: Oncology and hematology
• Keywords: bortezomib;velcade;multiple myeloma
• Description: Multiple myeloma is the second most prevalent and mostly fatal hematologic cancer. Further advances have been made in understanding the mechanisms involved in the myeloma pathogenesis and elucidation of critical signalling pathways as therapeutical targets. Proteasome inhibitors are the example of this new approach and bortezomib is the first agent in this class to enter clinical trials.